Pharmaceuticals - North America

North America

In 2024, the projected revenue in the Pharmaceuticals market is expected to reach an impressive US$664.40bn.
Within this market, the largest market is Oncology Drugs, which is projected to have a market volume of US$119.90bn in the same year.
Looking ahead, the revenue is anticipated to exhibit an annual growth rate of 5.98% from 2024 to 2028 (CAGR 2024-2028), resulting in a market volume of US$838.00bn by 2028.
When considering the global perspective, United States is expected to generate the highest revenue among all countries, with an estimated amount of US$636.90bn in 2024.
This showcases the dominance of the North American market in the Pharmaceuticals market industry.
The pharmaceutical market in North America is experiencing a surge in demand for personalized medicine and gene therapies.

Key regions: United States, China, Germany, Japan, Europe

Definition:
The Pharmaceuticals market covers remedies used to cure, treat, prevent, and diagnose diseases. These small molecule drugs or biologic medical products may be called drugs, medications, or medicines. Prescription drugs and over-the-counter (OTC) drugs are both included. Depending on the regulations in each country, these products are provided by pharmacies, hospitals, physicians, and/or drug stores, and/or they can be bought elsewhere. They may be administered in the form of pills, capsules, gels, ointments, injections, infusions, lozenges, or aerosols/sprays.

Structure:
The market is subdivided into Oncology Drugs, Anti-Diabetes Drugs, Anti-Rheumatic Drugs, Vaccines, Dermatological Drugs, Antiviral Drugs, Immunosuppressants, Bronchodilator Drugs, Sensory Organ Drugs, Anti-Hypertensive Drugs, Anti-Coagulants, Anti-Fibrinolytic Drugs, Multiple Sclerosis Drugs, Lipid-Lowering Agents and Other Pharmaceuticals. The Pharmaceuticals market is organized in markets that cover drugs used in specific medical fields, i.e., medicines for a specific disesase or a certain type of medicine. They include original brands, biosimilars, generics, and orphan drugs.The Oncology Drugs market covers pharmaceutical products specifically developed for the treatment and management of various cancers. The Anti-Diabetes Drugs market covers medications designed to manage blood glucose levels and improve insulin sensitivity in individuals with diabetes. The market Anti-Rheumatic Drugs includes pharmaceuticals specifically developed to alleviate symptoms, reduce inflammation, and modify the progression of rheumatic diseases. The Dermatological Drugs market covers pharmaceuticals formulated to treat and manage a wide range of skin conditions such as eczema, acne, and rosacea. The Antiviral Drugs market includes medications designed to treat viral infections and reducing the severity and duration of symptoms. The Immunosuppressants market covers pharmaceuticals that suppress the immune system's activity. The Bronchodilator Drugs market covers pharmaceuticals designed to relax and widen the airways in the lungs. The Sensory Organ Drugs market covers pharmaceuticals targeting the treatment of disorders and conditions affecting sensory organs such as the eyes, ears and nose. The Anti-hypertensive Drugs market covers pharmaceuticals designed to lower blood pressure levels. The Anti-Coagulants Drugs market covers pharmaceuticals developed to prevent the formation of blood clots or to dissolve existing clots. The Anti-Fibrinolytics Drugs market covers pharmaceuticals designed to inhibit the breakdown of blood clots. The Multiple Sclerosis Drugs market covers pharmaceuticals aimed at managing and modifying the course of multiple sclerosis. The Lipid-Lowering Agents market covers pharmaceuticals developed to reduce levels of cholesterol and other lipids in the blood. The Other Pharmaceuticals market provides information on additional specialties that are not covered by the main markets.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novartis, Roche, Pfizer, Merck & Co, Johnson & Johnson, AbbVie, Sanofi.

Market

Region

Region comparison

Currency

Analyst Opinion

The Pharmaceuticals market in North America has been steadily growing over the years.

Customer preferences: Customers in North America have shown a preference for prescription drugs over over-the-counter drugs due to the perception that prescription drugs are more effective. Additionally, there is a growing demand for personalized medicine and specialty drugs, which are often used to treat rare diseases.

Trends in the market: One of the major trends in the North American Pharmaceuticals market is the increasing use of biologics, which are drugs made from living cells. Biologics have shown to be effective in treating a range of diseases, including cancer and autoimmune disorders. Another trend is the growing use of digital health technologies, such as telemedicine and health apps, which are changing the way patients access healthcare and manage their health.

Local special circumstances: The United States is the largest market for Pharmaceuticals in North America, and one of the largest in the world. The country's aging population and high prevalence of chronic diseases have contributed to the growth of the market. Canada, on the other hand, has a smaller market size but has a strong focus on research and development, particularly in the areas of oncology and neuroscience.

Underlying macroeconomic factors: The North American Pharmaceuticals market is influenced by a range of macroeconomic factors, including government regulations, healthcare policies, and patent laws. The high cost of healthcare in the United States has led to increased scrutiny of drug prices and calls for greater transparency in pricing. In Canada, the government plays a larger role in setting drug prices, which has led to lower prices compared to the United States. The ongoing COVID-19 pandemic has also had an impact on the market, with increased demand for certain drugs and disruptions to supply chains.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.